A third of patients with lymph node-positive penile cancer don’t receive recommended care

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

One third of men with lymph node-positive penile cancer don’t receive a lymph node dissection, the recommended care associated with an overall survival advantage, researchers from Fox Chase Cancer Center have found. The paper appears in JAMA Oncology.

The researchers used the National Cancer Database to evaluate patient care at hospitals nationwide, and found that men had a better overall survival rate after undergoing a lymph node dissection, while neither chemotherapy nor radiation was associated with a survival benefit. But, they found that one third of patients did not undergo a lymph node dissection.

The National Comprehensive Cancer Network guidelines advocate for lymph node dissection or radiotherapy with consideration of perioperative chemotherapy for all patients with lymph node-positive penile cancer without metastasis.

Researchers also found that while the use of chemotherapy has increased over the past decade, rates remain below 50 percent. Older patients in particular were less likely to receive chemotherapy.

YOU MAY BE INTERESTED IN

I write a weekly blog for Georgetown University’s Lombardi Comprehensive Cancer Center community. Here I share an updated version of a blog post I wrote in September 2024, now supplemented by some poems I have written over the years that inspired paintings by my wife Harriet Weiner, who is a much better artist than I am a poet or writer. 
The Government Accountability Office, an independent, non-partisan congressional watchdog agency, found that NIH violated the Impoundment Control Act of 1974 when it cancelled nearly 2,000 research grants in an effort to comply with several of President Donald Trump’s executive orders, including “Ending Radical And Wasteful Government DEI Programs And Preferencing” (The Cancer Letter, Jan 24, 2025).

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login